术前胸肌前乳房再造中ADM与光滑圆形假体的风险因素与并发症预测
该多中心前瞻性观察队列研究纳入140例(221侧乳房)接受保留皮肤或乳头乳房切除后即刻胸肌前假体再造的患者,使用Braxon® ADM与光滑圆形假体。总并发症发生率为43.4%,再造相关并发症为14.4%。新辅助化疗增加再造相关并发症风险,而Braxon® Fast与延长抗生素预防为保护因素。
要点
- 胸肌前ADM辅助即刻乳房再造总并发症率43.4%,再造相关并发症率14.4%。
- 新辅助化疗显著增加再造相关并发症风险(OR=18.8)。
- Braxon® Fast与延长抗生素预防为再造相关并发症的保护因素。
核心结论
- 胸肌前ADM辅助即刻乳房再造并发症率可接受。
- 新辅助化疗增加再造相关并发症风险,Braxon® Fast与延长抗生素预防具保护作用。
研究设计与样本
- 术式为保留皮肤或乳头乳房切除后即刻胸肌前再造,使用Braxon® Regular或Fast ADM及Motiva®或Mentor®假体。
主要发现
- 平均年龄48.6岁,平均BMI 22.7 kg/m²。
- 共记录96例并发症(43.4%),其中乳房切除相关64例(29.0%),再造相关32例(14.4%)。
- 14.9%的病例需再次手术。
- 乳房切除皮瓣坏死(6.9%)和感染(3.6%)是导致假体取出(7.4%)的最常见并发症。
关键数值与推荐
- 新辅助化疗预测再造相关并发症(OR=18.8;p=0.026)。
- Braxon® Fast相比Braxon® Regular预测再造相关并发症(OR=0.092;p=0.013)。
- 延长抗生素预防预测再造相关并发症(OR=0.013;p=0.004)。
- 未发现与乳房切除相关结局相关的预测因素。
临床怎么用
- 术前应评估新辅助化疗史以识别再造相关并发症高危患者。
- 可考虑选用Braxon® Fast ADM并延长抗生素预防以降低再造相关并发症风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prepectoral implant-based reconstruction using acellular dermal matrices (ADMs) has emerged as a viable option for immediate breast reconstruction (IBR) following mastectomy. This multicenter, prospective observational cohort study evaluated the outcomes of prepectoral reconstruction using Braxon® ADMs and smooth round implants across two specialized Italian cancer centers. METHODS: From April 2019 to December 2024, 140 female patients (221 breasts) underwent skin- or nipple-sparing mastectomy followed by immediate prepectoral reconstruction with either Braxon® Regular or Braxon® Fast ADM and Motiva® or Mentor® implants. Comprehensive demographic, surgical, and postoperative data were collected. Complications were classified as mastectomy-related (e.g., bleeding and mastectomy skin flap necrosis) or reconstruction-related (e.g., seroma, infection, and red breast syndrome). Binary logistic regression identified predictors of complications. RESULTS: The mean patient age was 48.6 years, with a BMI of 22.7 kg/m². A total of 96 complications (43.4%) were recorded: 64 were mastectomy-related (29.0%) and 32 were reconstruction-related (14.4%). Reoperation was required in 14.9% of the cases. Mastectomy flap necrosis (6.9%) and infection (3.6%) were the most frequent complications leading to implant removal in 7.4% of the cases. Logistic regression identified neoadjuvant chemotherapy (OR=18.8; p=0.026), Braxon® Fast compared to Braxon® Regular (OR=0.092; p=0.013), and extended antibiotic prophylaxis (OR=0.013; p=0.004) as predictors of reconstruction-related complications. CONCLUSIONS: Prepectoral IBR with Braxon® ADMs demonstrated acceptable complication rates. No predictors were associated with mastectomy-related outcomes. Braxon® Fast and prolonged antibiotics were protective against reconstruction-related events, while neoadjuvant chemotherapy increased the risk. These findings highlight the importance of patient selection and perioperative strategies, particularly in high-risk subgroups such as those receiving neoadjuvant chemotherapy.
引用
- Sorotos M, Firmani G, Paolini G, et al. Risk factors and complication predictors in prepectoral breast reconstruction using ADM and smooth round implants: An observational cohort study. J Plast Reconstr Aesthet Surg. 2026. PMID: 42302701. doi:10.1016/j.bjps.2026.05.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。